HIV prevention

Dapivirine Vaginal Ring and Oral PrEP Confirmed Safe for Use During Second Trimester: Insights from the DELIVER Trial

The Phase 3b DELIVER trial confirms that both the dapivirine vaginal ring and oral PrEP are safe and well-tolerated when initiated in the second trimester of pregnancy, showing no product-related serious adverse events and high rates of ter

Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER